AU2004294345B2 - Synthetic HLA binding peptide analogues and uses thereof - Google Patents

Synthetic HLA binding peptide analogues and uses thereof Download PDF

Info

Publication number
AU2004294345B2
AU2004294345B2 AU2004294345A AU2004294345A AU2004294345B2 AU 2004294345 B2 AU2004294345 B2 AU 2004294345B2 AU 2004294345 A AU2004294345 A AU 2004294345A AU 2004294345 A AU2004294345 A AU 2004294345A AU 2004294345 B2 AU2004294345 B2 AU 2004294345B2
Authority
AU
Australia
Prior art keywords
cells
peptide
synthetic peptide
human
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2004294345A
Other languages
English (en)
Other versions
AU2004294345A1 (en
Inventor
Javier Pinilla-Ibarz
David Scheinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34652399&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004294345(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2004294345A1 publication Critical patent/AU2004294345A1/en
Application granted granted Critical
Publication of AU2004294345B2 publication Critical patent/AU2004294345B2/en
Priority to AU2012202819A priority Critical patent/AU2012202819A1/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2004294345A 2003-12-01 2004-11-30 Synthetic HLA binding peptide analogues and uses thereof Expired AU2004294345B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012202819A AU2012202819A1 (en) 2003-12-01 2012-05-15 Synthetic HLA binding peptide analogues and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52595503P 2003-12-01 2003-12-01
US60/525,955 2003-12-01
PCT/US2004/040347 WO2005053618A2 (en) 2003-12-01 2004-11-30 Synthetic hla binding peptide analogues and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012202819A Division AU2012202819A1 (en) 2003-12-01 2012-05-15 Synthetic HLA binding peptide analogues and uses thereof

Publications (2)

Publication Number Publication Date
AU2004294345A1 AU2004294345A1 (en) 2005-06-16
AU2004294345B2 true AU2004294345B2 (en) 2012-02-23

Family

ID=34652399

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004294345A Expired AU2004294345B2 (en) 2003-12-01 2004-11-30 Synthetic HLA binding peptide analogues and uses thereof

Country Status (7)

Country Link
US (3) US7488718B2 (enExample)
EP (2) EP1708732B2 (enExample)
JP (1) JP2007516966A (enExample)
AU (1) AU2004294345B2 (enExample)
CA (1) CA2548135C (enExample)
ES (1) ES2402184T5 (enExample)
WO (1) WO2005053618A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127409A1 (en) * 2003-12-01 2006-06-15 Scheinberg David A Bcr-abl vaccines and methods of use thereof
JP2007516966A (ja) * 2003-12-01 2007-06-28 スローン−ケターリング インスティチュート フォー キャンサー リサーチ 合成ｈｌａ結合ペプチド類似体及びその使用方法
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
EP2010209B1 (en) * 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
WO2008048410A2 (en) * 2006-09-19 2008-04-24 Human Biomolecular Research Institute Diagnostic methods and genetic markers for alzheimer disease
PL2119778T3 (pl) * 2007-02-27 2016-04-29 Int Inst Cancer Immunology Inc Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie
EP2216041A4 (en) * 2007-11-20 2012-10-24 Nec Corp METHOD OF INDUCING A CYTOTOXIC T-CELL, CYTOTOXIC T-CELL INDUCTOR AND PHARMACEUTICAL COMPOSITION, AND VACCINE WITH THE INDUCTOR
CN101888852B (zh) 2007-12-05 2017-02-08 株式会社癌免疫研究所 癌症疫苗组合物
WO2009137872A1 (en) * 2008-05-14 2009-11-19 Simons Haplomics Limited Methods and compositions for the treatment of cancer
EP2608799B1 (en) 2010-08-24 2018-12-12 University of Pittsburgh - Of the Commonwealth System of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
AU2012291101B2 (en) 2011-07-29 2016-04-07 Riken Cell for use in immunotherapy which contains modified nucleic acid construct encoding Wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct
US9539299B2 (en) * 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
EP2914278B1 (en) 2012-11-05 2021-06-02 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
PL2945647T3 (pl) 2013-01-15 2021-03-08 Memorial Sloan Kettering Cancer Center Immunogenne peptydy wt-1 i sposoby ich zastosowania
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
EP3365356B1 (en) 2015-10-23 2023-06-28 President and Fellows of Harvard College Nucleobase editors and uses thereof
KR20250099263A (ko) 2015-11-20 2025-07-01 메모리얼 슬로안 케터링 캔서 센터 암 치료 방법 및 조성물
CA3034666A1 (en) 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating breast cancer
WO2018039203A1 (en) 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating multiple myeloma
JP7209963B2 (ja) 2016-11-30 2023-01-23 住友ファーマ株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
WO2018165631A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
JPWO2018181648A1 (ja) 2017-03-30 2020-02-13 大日本住友製薬株式会社 Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
WO2019083960A1 (en) 2017-10-24 2019-05-02 Oncopep, Inc. PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
EP3700575A1 (en) 2017-10-24 2020-09-02 Oncopep, Inc. Peptide vaccines and pembrolizumab for treating breast cancer
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
CN113382746A (zh) 2018-09-28 2021-09-10 大日本住友制药株式会社 注射用组合物
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
CA3182959A1 (en) 2020-05-12 2021-11-18 Sumitomo Pharma Co., Ltd. Pharmaceutical composition for treating cancer
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
CN118076382A (zh) 2021-08-12 2024-05-24 株式会社癌免疫研究所 用于治疗或预防癌症的药用组合物和方法
CN114149970B (zh) * 2021-11-09 2024-06-18 因诺伟(北京)生物医疗科技有限公司 一种外周血造血干细胞来源致敏树突状细胞的制备方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156316A (en) * 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
WO2001062920A2 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
WO2003037060A2 (en) * 2001-10-30 2003-05-08 Corixa Corporation Compositions and methods for wt1 specific immunotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
JP2007516966A (ja) * 2003-12-01 2007-06-28 スローン−ケターリング インスティチュート フォー キャンサー リサーチ 合成ｈｌａ結合ペプチド類似体及びその使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156316A (en) * 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
WO2001062920A2 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
WO2003037060A2 (en) * 2001-10-30 2003-05-08 Corixa Corporation Compositions and methods for wt1 specific immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Scardino et al. J. Immunol. 2002, 168(11), 5900-5906 *

Also Published As

Publication number Publication date
AU2004294345A1 (en) 2005-06-16
EP1708732B2 (en) 2016-05-18
EP1708732A4 (en) 2009-09-02
CA2548135C (en) 2014-04-22
EP1708732A2 (en) 2006-10-11
WO2005053618A3 (en) 2006-02-23
ES2402184T5 (es) 2016-10-25
WO2005053618A2 (en) 2005-06-16
US20050119185A1 (en) 2005-06-02
ES2402184T3 (es) 2013-04-29
US20060084609A1 (en) 2006-04-20
CA2548135A1 (en) 2005-06-16
JP2007516966A (ja) 2007-06-28
US7488718B2 (en) 2009-02-10
EP2478913A1 (en) 2012-07-25
EP1708732B1 (en) 2013-01-02
US7598221B2 (en) 2009-10-06
US20100239547A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
AU2004294345B2 (en) Synthetic HLA binding peptide analogues and uses thereof
CN104684577B (zh) 免疫原性wt-1肽及其使用方法
US10221224B2 (en) WT1 HLA class II-binding peptides and compositions and methods comprising same
US9265816B2 (en) Immunogenic WT-1 peptides and methods of use thereof
CN110078813A (zh) 免疫原性wt-1肽和其使用方法
JP4051602B2 (ja) 腫瘍抗原
Pinilla-Ibarz et al. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses
JPWO2001011044A1 (ja) 腫瘍抗原
WO2007047653A2 (en) Synthetic hla binding peptide analogues of mutant v617f jak2 enzyme and uses therefor
WO2007120603A2 (en) Immunogenic bcr-abl peptides and methods of use thereof
AU2012202819A1 (en) Synthetic HLA binding peptide analogues and uses thereof
US20060127409A1 (en) Bcr-abl vaccines and methods of use thereof
Uenaka et al. Murine leukemia RL 1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL)
HK40054568A (en) Immunogenic wt-1 peptides and uses thereof
HK40045843A (en) Immunogenic wt-1 peptides and methods of use thereof
HK40012212A (en) Immunogenic wt-1 peptides and methods of use thereof
Borras-Cuesta et al. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen
HK1233496A1 (en) Immunogenic wt-1 peptides and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired